Breaking News

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific notes SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

DuPont™ Liveo™ for Healthcare Silicone Solutions Is Introduced

September 15, 2020

DuPont is a globally recognized leader in silicone-based technology with more than 70 years of experience advancing healthcare through materials innovation, is introducing DuPont Liveo, a new brand name for its extensive range of silicone healthcare solutions. The news was announced today.

Inspired by the terms “live” and “to be alive,” the new Liveo brand name reflects DuPont Healthcare’s drive to create next-generation, innovative solutions that can help patients live life to the fullest.

“As the new name for the longest legacy in healthcare applied silicones brought by DOW CORNING, Liveo stands for smarter healthcare and positive patient outcomes,” says DuPont Liveo Healthcare Global Marketing Manager Jennifer Gemo Mathis.

More than a name change, the Liveo brand reinforces DuPont’s commitment in healthcare and renewed energy to build on more than 70 years of innovation development capabilities, regulatory and manufacturing know-how, and application expertise.

Historically marketed with a DOW CORNING or SILASTIC trade name, the product offering and packaging material are not changing, and all locations will continue to manufacture the same products, using the same rigorous processes and quality oversight as before. Looking ahead, the Liveo brand will reinforce DuPont’s competitive advantages and leadership positions in three key healthcare markets – Biopharmaceutical Processing, Pharmaceutical Solutions and Medical Devices.

“We are making significant investments in both capital and resources to strengthen our strategic capabilities to support our customers’ leadership in key healthcare industry market segments, and we are particularly proud of the contribution that our teams and products have provided to our customers without disruptions during the COVID-19 pandemic outbreak,” says DuPont Liveo Healthcare Global Business Director Eugenio Toccalino.

The Liveo brand product line includes pharma tubing and overmolded assemblies for single-use systems in biopharma processing, transdermal and topical drug delivery systems, medical adhesives for advanced wound care and ostomy care and wearables, silicone elastomers for a wide range of specialty medical devices, anti-flatulent active pharmaceutical ingredients, silicone antifoams, coating, fluids, emulsions and much more. The Liveo product line continues to be manufactured at the DuPont Healthcare Industries Materials Site (HIMS) in Hemlock, Michigan, USA, which is an ISO 9001:2015 and ISO 14000 registered site and FDA registered utilizing GMPs.

 

Latest Posts

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.